XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Other Income | 3 Months Ended
--- | ---
Dec. 31, 2021
Other Income |
Other Income | Note 3 Other Income Grant Income During the year ended September 30, 2021, the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX®2-73 related to Parkinson’s disease. The grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During the three months ended December 31, 2021 and 2020, the Company did not recognize any of this grant on its statements of operations. At December 31, 2021, an amount of $443,831 (September 30, 2021: $443,831) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statement of operations as the relating expenditures are incurred to offset the income. Research and development incentive income Research and development incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit, (the “R&D Incentive Credit”). During the three months ended December 31, 2021, the Company recorded research and development incentive income of $810,730 (AUD 1,116,362) (2020: $1,269,316 (AUD 1,735,962)) in respect of the R&D Incentive Credit for eligible research and development expenses incurred during the period.

X
- References No definition available. + Details
Name: | avxl_DisclosureOtherIncomeAbstract
Namespace Prefix: | avxl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | avxl_OtherIncomeDisclosureTextBlock
Namespace Prefix: | avxl_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration